Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Mutational landscape of B-cell post-transplant lymphoproliferative disorders.

Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN.

Br J Haematol. 2017 Jul;178(1):48-56. doi: 10.1111/bjh.14633. Epub 2017 Apr 17.

PMID:
28419429
2.

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Alikian M, Gale RP, Apperley JF, Foroni L.

Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar. Review.

3.

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.

Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, White H, Huggett JF, Foroni L.

Clin Chem. 2017 Feb;63(2):525-531. doi: 10.1373/clinchem.2016.262824. Epub 2016 Dec 15.

4.

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.

Gerrard G, Foong HE, Mudge K, Alikian M, Apperley JF, Foroni L.

Leuk Res. 2016 Oct;49:47-50. doi: 10.1016/j.leukres.2016.08.007. Epub 2016 Aug 13.

PMID:
27552679
5.

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.

Preuner S, Barna A, Frommlet F, Czurda S, Konstantin B, Alikian M, Machova Polakova K, Sacha T, Richter J, Lion T, Gabriel C.

Int J Mol Sci. 2016 Apr 29;17(5). pii: E642. doi: 10.3390/ijms17050642.

6.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG.

J Mol Diagn. 2016 Mar;18(2):176-89. doi: 10.1016/j.jmoldx.2015.09.005. Epub 2016 Feb 5.

7.

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.

Alonso-Dominguez JM, Grinfeld J, Alikian M, Marin D, Reid A, Daghistani M, Hedgley C, O'Brien S, Clark RE, Apperley J, Foroni L, Gerrard G.

Am J Hematol. 2015 Jan;90(1):20-6. doi: 10.1002/ajh.23857. Epub 2014 Oct 18.

8.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, ValgaƱon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L.

Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.

PMID:
24117365
9.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW.

Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.

10.

Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization.

Gerrard G, Mudge K, Foskett P, Stevens D, Alikian M, White HE, Cross NC, Apperley J, Foroni L.

Am J Hematol. 2012 Jul;87(7):717-20. doi: 10.1002/ajh.23212. Epub 2012 May 6.

11.

BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.

Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L.

Am J Hematol. 2012 Mar;87(3):298-304. doi: 10.1002/ajh.22272. Epub 2012 Jan 9. Review.

12.

A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.

Heathcote DA, Patel H, Kroll SH, Hazel P, Periyasamy M, Alikian M, Kanneganti SK, Jogalekar AS, Scheiper B, Barbazanges M, Blum A, Brackow J, Siwicka A, Pace RD, Fuchter MJ, Snyder JP, Liotta DC, Freemont PS, Aboagye EO, Coombes RC, Barrett AG, Ali S.

J Med Chem. 2010 Dec 23;53(24):8508-22. doi: 10.1021/jm100732t. Epub 2010 Nov 16.

PMID:
21080703
13.

WTX is rarely mutated in acute myeloid leukemia.

Owen C, Virappane P, Alikian M, Stasevich I, Summers K, Lillington D, Bonnet D, Burnett A, Mills K, Lister TA, Fitzgibbon J.

Haematologica. 2008 Jun;93(6):947-8. doi: 10.3324/haematol.12509. Epub 2008 May 6. No abstract available.

Supplemental Content

Loading ...
Support Center